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ABSTRACT 
 
In recent years, it has been recognized that regulatory T cells (Tregs) play a critical role in 
maintaining immune tolerance. Moreover, the expression of two markers named Helios and 
neurophilin-1 (NRP-1) has been highlighted in such cells. Helios, an intracellular transcription 
marker, largely differentiates twomost operative sub group of Tregs, namely naturally occurring 
(nTreg) and induced (iTreg) Tregs, and NRP-1 is reckoned as a membranous activity marker of 
Tregs. We aimed to count peripheral mononuclear cells expressing such markers in a group of 
type 1 diabetes patients to elucidate the possible role of Tregs in the pathogenesis of such disease 
and its complications.  
Blood samples from 61 adult patients with type 1 diabetes and 61 sex and age-matched 
healthy controls were tested to count two types of Tregs, namely naturally occurring and 
inducible types, according to the expression of cell surface markers of CD4/CD25/CD47–
FITC/PE/APC and intracellular markers of FoxP3/Helios–PE-CY5/eFlour450 by flow 
cytometry, respectively.We also investigated the relation between expression of such markers 
with HbA1c, urine albumin/creatinine ratio (UACR), and common carotid intima thickness 
(CIMT). 
The circulatory frequency of both Helios+ and Helios- T-cells were significantly decreased in 
patients compared to those in healthy controls (p<0.001). There was also a significant decrease in 
circulatory frequency of Helios+ NRP-1+ and Helios- NRP-1+ cells in the patients compared to 
controls (p=0.029).  
According to expression of Helios and NRP-1 markers, the number and function of both 
Tregs were decreased in diabetic patients. Moreover, the neurophilin expression was inversely 
associated with complications of type 1 diabetes. 
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INTRODUCTION 
 
Type 1 diabetes (T1D) is a T-cell–mediated 
disease caused, at least partly, by loss of 
immunological tolerance to self-antigens.
1 
One 
mechanism involved in maintenance of tolerance to 
such disease includes the presence of a specialized 
subset of regulatory T-cells (Tregs) expressing the 
transcription factor of Forkhead Box Protein P3 
(FoxP3) within the CD4
+
CD25
+
T-cell population.
2 
Tregs are generally classified into two categories, 
naturally occurring Tregs (nTregs) and 
inducible/adaptive Tregs (iTregs).
3 
nTregs primarily 
emerge from the thymus and have the 
CD4+CD25+FoxP3+Helios+ phenotype,
4-7
 whereas 
iTregs are generated in the periphery from naive T 
cells after antigen exposure
8 
and have the 
CD4+CD25+FoxP3+Helios-phenotype.
4,5,7,9 
CD4+CD25+FoxP3+ Tregs which arise both in the 
thymus and in the periphery as a consequence of 
exposure to antigens
8 
are immune response 
modulators of crucial importance in many 
physiological and pathological situations, which are 
characterized by their ability to inhibit antigen 
speciﬁc T lymphocyte activation.10 Even though the 
molecular and cellular mechanisms underlying their 
suppressive activity are under intense investigation, 
they are not yet totally elucidated.  
CD304, or Neuropilin-1 (NRP-1), a 
transmembrane C-type lectin on plasmacytoid 
dendritic cells,
11
 found originally as a semaphoring-III 
receptor in neurological synapses.
12,13
Expressing on 
human immune cells, NRP-1 plays a crucial role in 
both regulation
14
 and activation of immune responses 
through promotion of dendritic cell–CD4+ T-cell 
clustering via homotypic interaction.
13
Nowadays, 
NRP-1 is usually referred to as a marker of human 
Tregs.
15
 
A few studies have been carried out on Treg’s 
function in animals with type 1 diabetes.
6,16,17
 In our 
research, considering Helios as a differentiating 
marker of nTreg/iTreg and NRP-1 as a specified 
marker of Tregs’ (and not the auto-reactive T-cells) 
activity, we quantified the number of both Helios and 
NRP-1 expressing CD4+CD25+FoxP3+Tregs in 
peripheral blood of type 1 diabetic patients. We also 
investigated the relation between expression of such 
markers with HbA1c (as indicator of metabolic 
control of type of diabetes), urine albumin/creatinine 
ration (as indicator of diabetic nephropathy), and 
common carotid intima thickness (as indicator of 
diabetic vasculopathy). 
 
MATERIALS AND METHODS 
 
Patients 
This study was conducted on 122 cases, 61 of 
which were adult patients with type 1 diabetes and 61 
sex and age-matched healthy controls. Type 1 diabetic 
patients diagnosed for more than a year who were 
non-smoker, prescribed with no antihypertensive and 
lipid-profile altering drugs, and no history of cardiac 
events were included. Existence of hepatic, renal, 
articular, metabolic, endocrine and cardiovascular 
diseases, cancers, infections, auto-immunity, 
pregnancyand a history of using antihypertensive or 
lipid-lowering medicationswere our exclusion criteria. 
The protocol was approved by the local Committee of 
Ethics (No. 93101) and was in accordance with the 
Helsinki Declaration. Written informed consent was 
obtained from all participants. 
 
Sampling Protocol and Measurements 
Blood and urine samples were drawn at 08:00-
10:00 in the morning after 12 hours overnight fasting. 
CBC, HbA1c, creatinine, lipids (total cholesterol, 
LDL cholesterol, HDL cholesterol, VLDL cholesterol, 
and triglycerides) and urinary concentration of 
albumin and creatinine were evaluated using standard 
laboratory methods. An automatic cell counter 
Sysmex K4500 (Japan) counted blood cells and  
an immunoturbidometric method of Bayer 
Diagnostics Europe Ltd (Ireland) protocol measured 
HbA1c levels. Lipid profile was assessed using end-
point enzymatic methods through Beckman 
Instruments, Fullerton, California's protocol. Urine 
albumin and urine/serum creatinine were measured by 
enzymatic immunoassay and Jaffe´ methods, 
respectively. In order to define albuminuria through 
albumin/creatinine ratio measurement, 3 urine 
samples were obtained. 
 
Ultrasonography 
Having left all participants in supine position  
for at least 10 min in a quiet room at 22
o
C. An 
unaware reader of the subject’s clinical details 
performed ultrasonography according to standardized 
scanning protocol for the right and left common 
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carotid arteries using a medison v20 equipped with a 
linear 11 MHZ transducer (Medison/Samsung 
Medicine System GmbH, South Korea). On each 
common carotid artery, a 2cm segment proximal to 
the bulb region on far wall of the carotid was scanned 
by at least 100 points. All images were taken at end-
diastole and then stored digitally for subsequent off-
line analysis. Computer software analyzed the IMT 
distance automatically via arithmetically calculating a 
mean of the thickenings of the 2 above-mentioned 
segments. 
 
Mononuclear Cell Isolation 
Peripheral blood mononuclear cells were isolated 
from 4mL of fresh blood sample with EDTA 
anticoagulant agent on ficoll-hypaque (Biosera, South 
Korea). Having added fixation/permeabilization 
solution to each tube, we stained each test tube for 
cell surface markers of CD4/CD25/CD304–
FITC/PE/APC and intracellular markers of 
FoxP3/Helios–PE-CY5/eFlour450 anti-human 
monoclonal antibodies according to manufacturer's 
instructions (e Bioscience,-USA). The other tube of 
each participant was intended as isotype control. In 
summary, the following steps were taken: 
For each sample and its control tube, 100 
microliters equivalent to 1million cells were added to 
each flow cytometry tube. 20 µL of the staining 
cocktail containing 1 µcg CD4 and CD304 and 0.125 
µcg CD25 were added to sample tubes. For each 
isotope control tube, 20 µL (microgram) of mouse PE 
IgG1 and 1 µg of mouse APC IgG1 were added. Cells 
were washed in staining buffer and were incubated in 
1 mL fixation/permeabilization buffer at 4°C for 60 
minutes. After being washed twice with 2mL of 1x 
dilution of permeabilization buffer, 10 µL of anti-
human Helios/FoxP3 to the sample tube and 2.5 µL of 
rat IgG2a-PE-CY isotope control were added to 
control tubes. The tubes were incubated at 4°C for 30 
minutes. Having washed the cells, we enumerated at 
least 50000 events using a 4-coloured (BD-USA) 
FACScalibur. For such purpose after gating of 
CD4+CD25+FoxP3+Treg lymphocytes, the cells 
expressing both markers Helios and CD304 were 
counted. 
 
Statistical Analysis 
The comparison of different markers in two groups 
of diabetic and non-diabetic participants was 
performed using Chi-square test. Regards to their 
distribution, we quantitated the variables using t-test 
or Mann-Whitney test. The relationship between the 
variables was determined by conducting Pearson test. 
Considering the different confounding factors, we 
analysed the data using logistic regression model. All 
analyses were made by the SPSS package (Version 
16.0. Chicago, SPSS Inc., USA). 
RESULTS 
 
The participants' demographic and clinical data are 
shown in Table1.  
The circulatory frequency of 
CD4+CD25+FoxP3+Helios+ (p<0.001), 
CD4+CD25+FoxP3+Helios- (p<0.001), and 
CD4+CD25+FoxP3+Helios+NRP-1+ Tregs were 
significantly lower than those in controls (p=0.029). 
Eliminating the confounding effects of factors 
including age, BMI, haemoglobin, blood lipid status 
and creatinine by Pearson Correlation Coefficient,  
we revealed a non-significant negative correlation 
between CD4+CD25+FoxP3+Helios+ Tregs with 
UACR (r=-0.199) and HbA1C (r=-0.203). There  
was no linear correlation between 
CD4+CD25+FoxP3+Helios+ Tregs and CIMT 
(r=0.001). Moreover, there was similar correlation 
between CD4+CD25+FoxP3+Helios- Tregs and 
UACR (r=-0.151) but not with CIMT and HbA1C. 
Non-significant, univariate, inverse correlations were 
observed between CD4+CD25+FoxP3+Helios+NRP-
1+ cells with CIMT (r=−0.149) and HbA1C 
(r=−0.151) (Table 2). 
Using multivariate regression analysis to 
investigate the effect of different basic and clinical 
factors on diabetes complications, we showed 
significant effects of CD4+CD25+FoxP3+Helios+ 
Tregs on UACR (P=0.034) in the presence of diastolic 
blood pressure, HDL and HbA1C; 
CD4+CD25+FoxP3+Helios+NRP-1+ Tregs on CIMT 
(p=0.05); CD4+CD25+FoxP3+Helios+ Tregs 
(p=0.012) and CD4+CD25+FoxP3+Helios- Tregs 
(p=0.033) on HbA1c in the presence of TG (p=0.011) 
and Hct (p=0.002).(data not shown) 
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Table 1. Distribution of basic and clinical characteristic of type 1 diabetic patients and healthy individuals 
Parameters Healthy Patients p value 
Sex (male/female) 30/31 28/33 0.717 
Age (years) 13.21±40.8 12.93±4.09 0.707 
Duration of diabetes (months) - 78.1±59.6 - 
BMI (kg/m2) 21.28±3.99 21.34±4.46 0.937 
Systolic BP (mmHg) 114.44±8.91 112.62±9.95 0.29 
Diastolic BP (mmHg) 73.05±9.66 71.85±8.53 0.47 
Creatinine (mg/dl) 0.97±0.17 0.92±0.19 0.16 
Total cholesterol (mg/dl) 162.26±24.03 166.74±24.23 0.42 
Triglyceride (mg/dl) 76.28±24.6 75.34±27.54 0.84 
HDL(mg/dl) 38.44±6.18 40±7.4 0.21 
VLDL(mg/dl) 16.6±6.77 14.95±5.82 0.15 
LDL(mg/dl) 105.6±18.26 111.48±17.84 0.076 
HbA1c (%) 4.73±0.71 6.81±1.55 <0.001 
RBC )Mil/µL) 4.99±425 5.13±1.28 0.43 
Hemoglobin (g/dL) 14.07±2.12 13.81±1.25 0.41 
Hematocrit (%) 43.19±3.68 41.66±3.27 0.017 
CIMT* 0.388±0.034 0.447±0.066 <0.001 
UACR** 3.93±2.87 10.58±10.23 <0.001 
CD4+CD25+FoxP3+Helios+ 1.33±0.91 0.68±0.63 <0.001 
CD4+CD25+FoxP3+Helios- 1.2±0.79 0.73±0.6 <0.001 
CD4+CD25+FoxP3+Helios+NRP-1+ 0.087±0.11 0.053±0.042 0.029 
CIMT: carotidintima media thickness; UACR: urinealbumin/creatinine ratio 
 
Table 2.Pearson correlation coefficient between different Tregs and complications of type 1 diabetes 
Diabetic complications Tregs UACR CIMT HbA1C 
CD4+CD25+FoxP3+Helios+ -0.199 
(0.125) 
0.001 
(0.996) 
-0.203 
(0.117) 
CD4+CD25+FoxP3+Helios- -0.151 
(0.246) 
-0.051 
(0.701) 
-0.042 
(0.747) 
CD4+CD25+FoxP3+Helios+NRP-1+ -0.005 
(0.972) 
-0.149 
(0.261) 
-0.151 
(0.247) 
UACR: urine albumin/creatinine ration; CIMT: carotid intima thickness; T1D: Type 1 diabetes 
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DISCUSSION 
 
Multiple defects within the innate and adaptive 
immune systems are associated with the development 
of type 1 diabetes.
18
 Collectively, these defects lead to 
an imbalance in immune regulation that facilitates the 
expansion of pathogenic autoreactive T- and B-cells, 
resulting in the eventual destruction of insulin-
producing β-cells.19,20 In recent years, appreciation has 
grown for the critical role Tregs on immune 
tolerance.
19
 Increasing evidence in mouse models of 
type 1 diabetes (T1D), as well as other autoimmune 
disorders, suggests that there are defects in Treg-
mediated suppression.
21 
Immuno-therapies targeting T 
cells, and resetting the balance between T effectors and 
Tregs, have had some initial success in preserving beta 
cell function.
22 
Two main subsets of CD4+Tregs, 
natural and inducible, which differ in terms of their 
development, specificity, mechanism of action and 
dependence on T-cell receptor and co-stimulatory 
signaling
8
are defined by expression of surface markers 
and production of specific cytokines that dictate their 
mode of action.
5
 
Our study showed the decreased expression of the 
new markers of Helios (commonly reported as a 
marker of nTregs) and NRP-1 (as a marker of Treg 
activation) on circulatory Tregs of type 1 diabetic 
patients. Such decreases may affect type 1 diabetes 
immune pathogenesis. In line with our study, others 
have showed a decreased expression of Helios on 
Tregs of type 1 diabetic patients.
23
 
Considering the nearly equal reduced number of 
both CD4+CD25+FOXP3+Helios+ and 
CD4+CD25+FoxP3+Helios- Tregs, we may conclude 
that there is no difference in expression level of Helios 
marker on different types of human Tregs in type 1 
diabetes. In view of so-called marker as the identifier 
of naturally occurring versus inducible type of Tregs, 
decreased number of both types of Tregs may be a 
reason (or at least a predisposing factor) of type 1 
diabetes. Also, considering NRP-1 as an activation 
marker of Tregs, we report a decrease of circulatory 
CD4+CD25+FOXP3+Helios+NRP-1+ frequencies 
among type 1 diabetics. Such concept may mean that 
the immunomodulatory effects of Tregs could prevent 
type 1 diabetes. In line with this idea, other studies 
have been stated that NRP-1+ cells show more roles in 
suppressing and controlling the immune system than 
that of NRP-1- cells.
24
 
Having omitted the possible confounding effects of 
age, BMI, haemoglobin, creatinine and serum lipid 
status on Treg frequencies, we showed that there was 
still a significant difference between the decreased 
numbers of Tregs with type 1 diabetes. It may be 
concluded more confidently now that the diabetes has 
an effect on the number and function of Treg cells. 
Although non-significant, there was a relation 
between Treg frequencies and diabetic complications 
of poor metabolic control, nephropathy and 
vasculopathy. A reverse relation between number  
of CD4+CD25+FOXP3+Helios+NRP-1+cells with 
diabetic nephropathy and HbA1c levels, as an indicator 
of metabolic control of diabetes, was seen in our study. 
It may mean that there is less NRP-1-dependent 
activation onTregs in uncontrolled type 1 diabetes. 
Such matter also applies to vasculopathy complication 
of diabetes, as the number of NRP-1 expressing cells 
was inversely related to vasculopathy, although it was 
not significant.  
In recent years, due to possibility of using Tregs in 
biologic treatment of common auto-immune diseases 
such as diabetes and multiple sclerosis and notable 
advantages of this method compared to conventional 
therapies, identifying the subgroups of Tregs and their 
specific cell markers has become an important matter 
of interest.
25
 In line with this idea, our study proposes 
Treg therapy methods with such mentioned markers as 
a new promising therapeutic method.
3
 There are also 
evidence for the imbalance of Th1/Treg cells 
(dramatically decrease of CD4+CD25+Tregs and 
improvement of Th1 cells) in T1D ,which may have 
significant impacts on the prevention of the disease and 
treatment of the patients.
26
 
The main limitation of our study is lack of 
longitudinal data that could be taken through serial 
samples to monitor the changes of Tregs as well  
as PDCs. This limitation allowed just a cross-sectional 
analysis of such cell profile of only limited robustness. 
According to expression of Helios and NRP-1 
markers, the number and function of both naturally 
occurring and inducible Tregs were decreased in 
diabetic patients. Moreover, the NRP-1 expression was 
inversely associated with T1D complications. 
Therefore, pharmacologic stimulation of such markers 
may direct immune responses towards tolerance and 
prevent the development or even the onset of diabetes 
T. Khamechian, et al. 
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in susceptible individuals. 
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